A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid Malignancies

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526215-10-00

Enrollment

Registered

2026-09-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory or Relapsed Solid Malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Sep 15, 2026